Adaptimmune Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Adaptimmune Therapeutics has a total shareholder equity of $96.3M and total debt of $25.0M, which brings its debt-to-equity ratio to 25.9%. Its total assets and total liabilities are $321.7M and $225.4M respectively.
Key information
25.9%
Debt to equity ratio
US$24.95m
Debt
| Interest coverage ratio | n/a |
| Cash | US$214.79m |
| Equity | US$96.27m |
| Total liabilities | US$225.43m |
| Total assets | US$321.70m |
Recent financial health updates
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Recent updates
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Adaptimmune slips as Barclays initiates with an underweight rating
May 28Financial Position Analysis
Short Term Liabilities: ADAP's short term assets ($253.8M) exceed its short term liabilities ($82.1M).
Long Term Liabilities: ADAP's short term assets ($253.8M) exceed its long term liabilities ($143.4M).
Debt to Equity History and Analysis
Debt Level: ADAP has more cash than its total debt.
Reducing Debt: ADAP's debt to equity ratio has increased from 0% to 25.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADAP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ADAP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.